Phase 3
N=330
Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial
Amyotrophic Lateral Sclerosis
Bottom Line
View on ClinicalTrials.gov: NCT00035815 ↗Enrolled (actual)
330
Serious AEs
9.1%
Results posted
Feb 2013
Primary outcome: Primary: Rate of Change in Composite Manual Muscle Testing (MMT) Score — 0.44; 0.39 MMT units per month — p=0.529
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Insulin like growth factor, type 1 (Drug); Placebo (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Mayo Clinic
- Primary completion
- Aug 2007
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Rate of Change in Composite Manual Muscle Testing (MMT) Score |
0.44; 0.39 | 0.529 |
| SECONDARY Number of Participants Alive and Tracheostomy-free at 24 Months |
93; 90 | 0.415 |
| SECONDARY Rate of Change in ALS Functional Rating Scale. |
2.5; 2.2 | 0.321 |
Summary
The purpose of this multicenter study is to determine if insulin-like growth factor-1 (IGF-I) slows the progressive weakness in amyotrophic lateral sclerosis (ALS) patients. Study participants will be followed for 2 years once enrolled. They will receive either placebo or the active IGF-I. Examinations will take place at approximately 6-month intervals.
Eligibility Criteria
Inclusion Criteria
Patients entering this study:
- Are between the ages of 18-80 years old.
- Legal residents of the United States or Canada.
- Have a history of a chronic onset of a progressive motor weakness of less than 24 months duration.
- Fulfill El Escorial criteria of probable or definite ALS.
- If female, are surgically sterile, two years postmenopausal, or if of child-bearing potential, must be using a medically acceptable method of birth control and agree to continue use of this method for the duration of the study. Acceptable methods include a barrier method with spermicide, oral contraceptives (normal doses are acceptable; low dose oral contraceptives or contraceptive implants must be used with a barrier method), intrauterine device (IUD), or abstinence. Have a negative pregnancy test.
- Are able to comply with protocol requirements.
- Can provide written informed consent.
- Have a manual muscle testing score of less than 8.
- Have a forced vital capacity by pulmonary function testing *60% predicted.
Exclusion Criteria
Patients entering this study will not:
- Have any of the following conditions: renal disease (Creatine > 2.0) or other active systemic disease
- Have any clinically significant abnormalities on the prestudy laboratory evaluation, physical examination, ECG, chest x-ray or ophthalmologic exam.
- Have any clinically significant medical condition (e.g., within six months of baseline, had myocardial infarction, angina pectoris, and/or congestive heart failure) that, in the opinion of the investigator, would compromise the safety of patient.
- Have Type I or Type II diabetes.
- Have a history of cancer including melanoma with the exception of localized skin cancers (with no evidence of metastasis, significant invasion, or re-occurrence within three years of baseline) and carcinoma in-situ of the cervix (women only).
- Have used an investigational drug within 30 days of baseline visit.
- Have had a tracheostomy.
- Have a Beck's Depression Inventory score * 12.
- Have legal residency outside of the United States or Canada.
- Be pregnant or breast-feeding.
Data sourced from ClinicalTrials.gov (NCT00035815). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.